Table 2.
Histopathological classification*, age and development of end-stage renal disease in hAPLN patients
| Patient number | Biopsies prior to study start (age) | Biopsy prior to hAPLN (age) | Biopsy I (age) | Biopsy II (age) | Biopsy III (age) | ESRD (age) |
|---|---|---|---|---|---|---|
| 1 | - | - | hAPLN (54) | - | - | - |
| 2 | II (36) | - | hAPLN/IV (38) | II (39) | V (41) | + (55) |
| 3 | - | - | hAPLN (49) | hAPLN (53) | - | - |
| 4 | hAPLN (8) | - | hAPLN/II (28) | - | - | + (28) |
| 5 | - | IV (35) | hAPLN (47) | - | - | - |
| II (36) | ||||||
| IV (39) | ||||||
| IV(42) | ||||||
| 6 | IV (26) | V (35) | hAPLN/V (36) | - | - | - |
| IV (28) | ||||||
| III (29) | ||||||
| 7 | - | II (40) | hAPLN/V (43) | - | - | - |
| 8 | - | II (27) | hAPLN (29) | Scarring (29) | hAPLN (34) | + (38) |
| 9 | - | III (25) | hAPLN/II (26) | - | - | - |
| 10 | V (16) | V (22) | hAPLN/V (27) | V (33) | - | - |
| V (23) | ||||||
| V (24) | ||||||
| V (26) | ||||||
| 11 | II + V (24) | - | hAPLN/II + V (52) | - | - | - |
| 12 | - | - | hAPLN/V (30) | hAPLN/V (33) | - | + (36) |
| 13 | - | - | hAPLN/V (58) | V (59) | - | - |
| 14 | - | - | hAPLN (61) | - | - | - |
| 15 | - | - | hAPLN (55) | hAPLN (58) | - | + (58) |
| 16 | V (56) | - | hAPLN (62) | - | - | + (66) |